What is Endostim?
EndoStim operates at the intersection of medical device innovation and chronic disease management. By focusing on patients who remain symptomatic despite pharmacological interventions, the company has carved out a specialized niche in the gastroenterology market. The EndoStim System represents a first-in-class approach to reflux control, utilizing neurostimulation to restore physiological function. As the company continues to refine its clinical data and regulatory pathway, it remains a critical player in the evolving landscape of neuromodulation and digestive health, aiming to provide a long-term alternative to traditional surgical or pharmaceutical treatments.
How much funding has Endostim raised?
Endostim has raised a total of $94.6M across 12 funding rounds:
Private Equity
$5.5M
Private Equity
$14.1M
Series C
$9.1M
Unspecified
$11.2M
Private Equity
$6.4M
Private Equity
$2.5M
Series D
$25M
Private Equity
$12.1M
Private Equity (2011): $5.5M, investors not publicly disclosed
Private Equity (2012): $14.1M, investors not publicly disclosed
Series C (2013): $9.1M led by Billiken Angels Network and Prolog Ventures
Unspecified (2013): $11.2M, investors not publicly disclosed
Private Equity (2014): $6.4M, investors not publicly disclosed
Private Equity (2015): $2.5M, investors not publicly disclosed
Series D (2016): $25M with participation from Wellington Partners, Endeavour Vision, Sante Ventures, and Gimv
Private Equity (2017): $12.1M, investors not publicly disclosed
Key Investors in Endostim
Sante Ventures
A specialized investment firm focused on the biotech, medtech, and healthtech sectors, managing over $1 billion in capital to drive patient health outcomes.
Wellington Partners
A prominent European venture capital firm that supports early- and growth-stage life science companies in transforming breakthrough technologies into global market leaders.
Prolog Ventures
A venture capital firm dedicated to supporting startups that promote healthy living, sustainability, and wellness through innovative agricultural and health-focused solutions.
What's next for Endostim?
Looking ahead, EndoStim is positioned to leverage its significant capital reserves to navigate the complex regulatory environments required for broader market adoption. The company's strategic roadmap likely involves expanding clinical evidence to support its investigational use cases and potentially securing approvals in key global markets. By maintaining a focus on high-impact medical technology, EndoStim is well-equipped to scale its operations and address the unmet needs of millions suffering from chronic digestive disorders, ultimately transitioning from a research-heavy entity to a commercial-stage leader in the medtech sector.
See full Endostim company page
